Figure 4. Sivelestat is effective in Th17 EAE but not in Th1 EAE.

(A, B) Clinical scores from mice with passive experimental autoimmune encephalomyelitis (EAE) induced by adoptive transfer of Th17 (A) or Th1 (B) cells. Mice were treated with the indicated dose of Sivelestat or PBS i.p. every day from day 6 to 16 after transfer. Arrows depict initiation and termination of treatment. Results represent mean clinical score of 5–14 mice per group. Error bars represent means ± SEM. *p < 0.05, ** p < 0.01, # p < 0.005. (C–F) Histology of spinal cord and brain sections from Th17- or Th1-induced EAE mice treated with Sivelestat or PBS. Sections of spinal cord and brain were obtained 9 days after transfer and stained with H&E (C) and Luxol fast blue (F). Scale bars: 100 µm (C), 200 µm (F). Quantification of number of inflammatory foci in spinal cord (D) and brain (E). Data represent mean ± SEM of three mice per group.*p < 0.03, **p < 0.009. (G–I) Concentration of IL-17 (G), IL-2 (H) and IL-5 (I) from supernatants of MOG_35–55-stimulated spleen cells taken from mice 9 days after transfer of encephalitogenic Th17 or Th1 cells. Mice were treated with Silvelestat or PBS starting at day 6. Data represent mean ± SEM of three mice per group. *p < 0.05.